Exchange: NASDAQ·Updated 07:42 PM EDT
News
all
press releases
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ:UNCY) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws and other unlawful business...
Business Wire
More News
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ: UNCY) investors concerning the Companys possible violations of the federal...
Business Wire
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ: UNCY) investors concerning the Companys possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE THERAPEUTICS, INC...
Business Wire
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ: UNCY) on behalf of investors concerning the Companys possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON UNICYCIVE THERAPEUTICS, INC...
Business Wire
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
The law firm of Kirby McInerney LLP is investigating potential claims against Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ:UNCY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other...
Business Wire
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval
Unicycive Therapeutics said on Tuesday that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate.
Stocktwits
Why Is Unicycive Therapeutics Stock Falling Tuesday?
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again over third-party manufacturing issues.read more...
Benzinga
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time?
Unicycive Therapeutics said it received a Complete Response Letter from the U.S. Food and Drug Administration due to previously identified deficiencies at a third-party manufacturing facility.
Stocktwits
US Stocks Mixed; Home Prices Increase 1.1% In April
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up 0.09%. Edible Garden AG up 87%, Unicycive Therapeutics down 46%.read more...
Benzinga
UNCY Stock Rallies 8% As Retail Traders Anticipate FDA Clearance For Lead Drug Candidate
Unicyive is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.
Stocktwits

Advertisement|Remove ads.